10x Genomics (TXG) Tops Q4 EPS by 4c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to 10x Genomics (TXG) Tops Q4 EPS by 4c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance

February 18, 2020 4:02 PM EST

Full year 2019 revenue growth of 68% over prior year

PLEASANTON, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019.

Recent Highlights

Revenue of $75.3 million for the fourth quarter and $245.9 million for the full year of 2019, representing 49% and 68% increases, respectively, over the corresponding periods of 2018Total of 1,666 Chromium instruments sold as of December 31, 2019Initiated shipments of the Visium Spatial Gene Expression Solution

Fourth Quarter 2019 Financial Results... More